Developer docs
API playgroundTry for free, no card

Search company profiles

HAVAH Therapeutics

Full company profile

uuid000413a

Namestring
HAVAH Therapeutics
Legal namestring
Havah Therapeutics Pty Ltd
Websiteurl
havahtx.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNorth Adelaide, Australia
HQ citystring
North Adelaide
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hormonal breast cancer therapy, androgen receptor agonists, subcutaneous implant therapeutics, clinical stage biopharmaceuticals, DCIS treatment development
Industry1 code
PRIMARYHLAKAFAJ
Breast Oncology
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Breast Cancer Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical stage biotech company. Once commercialized, the company will generate revenue through sales of its T+Ai hormonal implant therapy for breast cancer treatment and prevention. Target indications include DCIS, early-stage ER+ breast cancer, and prevention of hormonal refractory disease.

havahtx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1T+Ai
Description

Combination treatment containing testosterone and anastrozole in a subcutaneous extended-release pellet therapy for breast cancer prevention and treatment.

havahtx.com
Core offering1 text field

HAVAH Therapeutics is a clinical-stage biopharmaceutical company developing androgen-based hormonal therapies for breast disease. Its lead candidate HAV-088 is a first-in-class androgen receptor agonist delivered through a proprietary T+Ai subcutaneous extended-release pellet that combines testosterone and low-dose anastrozole to maintain intramammary DHT levels, supporting antiproliferative and anti-inflammatory cellular processes for treatment of DCIS, ER+ breast cancer, and prevention of hormonal refractory disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Statistically significant reductions in mammographic breast density (MBD) and Background Parenchymal Enhancement (BPE), both known indicators of breast cancer risk
+2 more records
Product overview1 text field

HAVAH Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of androgen-based therapies for breast disease. The core technology is the T+Ai™ platform—a proprietary subcutaneous extended-release pellet combining testosterone with anastrozole. The lead product candidate, HAV-088, leverages this technology to deliver first-in-class androgen receptor agonist therapy for hormone receptor positive breast cancer and DCIS. The company has over 3,500 woman-years of clinical exposure across its programs. The product portfolio centers on 'endocrine steering'—targeted modulation of hormonal balance in breast tissue to achieve more nuanced hormonal regulation than traditional therapies. The T+Ai pellet provides precise delivery of testosterone for women with a unique PK profile that drives the hormonal milieu of the breast.

Product and service1 record
1HAV-088
CategoryBreast Cancer Therapeutics / Hormonal Implant Therapy
Description

First-in-class androgen receptor agonist delivered as a subcutaneous implant that combines testosterone and anastrozole for the treatment of hormone receptor positive breast cancer, specifically targeting DCIS and high-risk premenopausal women. The product leverages the proprietary T+Ai extended-release pellet technology to maintain breast tissue DHT levels, drive antiproliferative effects, and support anti-inflammatory cell function.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

QLHC initiated the landmark RECAST DCIS Phase 2 platform trial evaluating alternative DCIS treatments. Havah Therapeutics is one of three investigational endocrine therapy arms being evaluated in this trial, which aims to revolutionize DCIS treatment and reduce unnecessary surgeries. The trial will enroll over 300 patients across 40 US sites.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct partner running the RECAST DCIS Phase 2 platform trial in which HAV-088 is one of three investigational endocrine arms; highly relevant as the operational and clinical comparator environment for Havah's lead program.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for breast cancer and breast health, including DCIS and hormonal therapies. Comparable as a small-cap US oncology company pursuing novel endocrine mechanisms in breast disease.

TypeDirect peer
Description

Clinical-stage oncology company developing targeted endocrine therapies for ER+ breast cancer. Comparable in stage, mechanism focus (novel endocrine modulation), and target indication overlap with HAV-088.

TypeDirect peer
Description

Clinical-stage women's oncology company developing therapies for hormone-driven cancers including ER+ breast cancer. Comparable as a small-cap peer targeting hormonal mechanisms in breast cancer.

TypeDirect peer
Description

Privately held women's health oncology company focused on ER+ breast cancer therapies, including novel endocrine agents. Comparable in size, focus, and clinical-stage positioning to Havah.

TypeOthers
Description

Public Nasdaq clinical-stage biotech led by Havah board director Ron Martell. Relevant as a comparable capital-markets-stage biotech with director-level overlap and similarity in fundraising profile.

TypeEmerging player
Description

ASX-listed clinical-stage biotech also led by former Havah CEO Kathy Harrison. Comparable as an Australian-listed small-cap biotech transitioning through clinical development.

TypeBroad incumbent
Description

Clinical-to-commercial stage oncology company with programs in ER+ breast cancer (vepdegestrant). Comparable as a breast cancer specialist with more advanced clinical stage and broader endocrine pipeline.

TypeBroad incumbent
Description

Large commercial medical device and diagnostics company in women's health/breast cancer (acquired Bolder Surgical, led by Havah's CFO previously). Comparable as a strategic acquirer and broad incumbent in breast cancer workflows.

TypeOthers
Description

Clinical-stage biotech where CEO Matt Brewer previously served as CBO and raised $65M. Comparable as a small clinical-stage biotech where the current leadership has direct execution experience.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HAVAH Therapeutics

Breast Cancer Therapeuticshavahtx.com

HAVAH Therapeutics firmographics

Firmographics
Name
HAVAH Therapeutics
Legal name
Havah Therapeutics Pty Ltd
Website
https://havahtx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

HAVAH Therapeutics industry classification

Industry
Product category
Breast Cancer Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAFAJ
Breast Oncology

Keywords

  • Hormonal breast cancer therapy
  • Androgen receptor agonists
  • Subcutaneous implant therapeutics
  • Clinical stage biopharmaceuticals
  • DCIS treatment development

Where HAVAH Therapeutics is headquartered

Location

Headquarters

HQ city
North Adelaide
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

HAVAH Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical stage biotech company. Once commercialized, the company will generate revenue through sales of its T+Ai hormonal implant therapy for breast cancer treatment and prevention. Target indications include DCIS, early-stage ER+ breast cancer, and prevention of hormonal refractory disease.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

HAVAH Therapeutics product offering

Product offering

Core offering

HAVAH Therapeutics is a clinical-stage biopharmaceutical company developing androgen-based hormonal therapies for breast disease. Its lead candidate HAV-088 is a first-in-class androgen receptor agonist delivered through a proprietary T+Ai subcutaneous extended-release pellet that combines testosterone and low-dose anastrozole to maintain intramammary DHT levels, supporting antiproliferative and anti-inflammatory cellular processes for treatment of DCIS, ER+ breast cancer, and prevention of hormonal refractory disease.

Product overview

HAVAH Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of androgen-based therapies for breast disease. The core technology is the T+Ai™ platform—a proprietary subcutaneous extended-release pellet combining testosterone with anastrozole. The lead product candidate, HAV-088, leverages this technology to deliver first-in-class androgen receptor agonist therapy for hormone receptor positive breast cancer and DCIS. The company has over 3,500 woman-years of clinical exposure across its programs. The product portfolio centers on 'endocrine steering'—targeted modulation of hormonal balance in breast tissue to achieve more nuanced hormonal regulation than traditional therapies. The T+Ai pellet provides precise delivery of testosterone for women with a unique PK profile that drives the hormonal milieu of the breast.

Differentiator

Problem solved

Functional benefit

Brands

  • T+Ai: Combination treatment containing testosterone and anastrozole in a subcutaneous extended-release pellet therapy for breast cancer prevention and treatment.

Products and services

  • HAV-088 First-in-class androgen receptor agonist delivered as a subcutaneous implant that combines testosterone and anastrozole for the treatment of hormone receptor positive breast cancer, specifically targeting DCIS and high-risk premenopausal women. The product leverages the proprietary T+Ai extended-release pellet technology to maintain breast tissue DHT levels, drive antiproliferative effects, and support anti-inflammatory cell function.

Quantifiable outcome

  • Statistically significant reductions in mammographic breast density (MBD) and Background Parenchymal Enhancement (BPE), both known indicators of breast cancer risk
  • +2 more outcomes

Companies that use HAVAH Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

HAVAH Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

HAVAH Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Quantum Leap Healthcare Collaborative (QLHC)coreStrategic or Co-development PartnerQLHC initiated the landmark RECAST DCIS Phase 2 platform trial evaluating alternative DCIS treatments. Havah Therapeutics is one of three investigational endocrine therapy arms being evaluated in this trial, which aims to revolutionize DCIS treatment and reduce unnecessary surgeries. The trial will enroll over 300 patients across 40 US sites.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

HAVAH Therapeutics competitors and assessment

Company assessment

Direct peers

  • Quantum Leap Healthcare Collaborative: Direct partner running the RECAST DCIS Phase 2 platform trial in which HAV-088 is one of three investigational endocrine arms; highly relevant as the operational and clinical comparator environment for Havah's lead program.
  • Atossa Therapeutics: Clinical-stage biotech developing therapeutics for breast cancer and breast health, including DCIS and hormonal therapies. Comparable as a small-cap US oncology company pursuing novel endocrine mechanisms in breast disease.
  • Olema Oncology: Clinical-stage oncology company developing targeted endocrine therapies for ER+ breast cancer. Comparable in stage, mechanism focus (novel endocrine modulation), and target indication overlap with HAV-088.
  • Context Therapeutics: Clinical-stage women's oncology company developing therapies for hormone-driven cancers including ER+ breast cancer. Comparable as a small-cap peer targeting hormonal mechanisms in breast cancer.
  • Sermonix Pharmaceuticals: Privately held women's health oncology company focused on ER+ breast cancer therapies, including novel endocrine agents. Comparable in size, focus, and clinical-stage positioning to Havah.

Others

  • Jasper Therapeutics: Public Nasdaq clinical-stage biotech led by Havah board director Ron Martell. Relevant as a comparable capital-markets-stage biotech with director-level overlap and similarity in fundraising profile.
  • Ashvattha Therapeutics: Clinical-stage biotech where CEO Matt Brewer previously served as CBO and raised $65M. Comparable as a small clinical-stage biotech where the current leadership has direct execution experience.

Emerging players

  • Dimerix: ASX-listed clinical-stage biotech also led by former Havah CEO Kathy Harrison. Comparable as an Australian-listed small-cap biotech transitioning through clinical development.

Broad incumbents

  • Arvinas: Clinical-to-commercial stage oncology company with programs in ER+ breast cancer (vepdegestrant). Comparable as a breast cancer specialist with more advanced clinical stage and broader endocrine pipeline.
  • Hologic: Large commercial medical device and diagnostics company in women's health/breast cancer (acquired Bolder Surgical, led by Havah's CFO previously). Comparable as a strategic acquirer and broad incumbent in breast cancer workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

HAVAH Therapeutics social profiles

Digital presence

HAVAH Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HAVAH Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

HAVAH Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HAVAH Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HAVAH Therapeutics

What does HAVAH Therapeutics do?

HAVAH Therapeutics is a clinical-stage biopharmaceutical company developing androgen-based hormonal therapies for breast disease. Its lead candidate HAV-088 is a first-in-class androgen receptor agonist delivered through a proprietary T+Ai subcutaneous extended-release pellet that combines testosterone and low-dose anastrozole to maintain intramammary DHT levels, supporting antiproliferative and anti-inflammatory cellular processes for treatment of DCIS, ER+ breast cancer, and prevention of hormonal refractory disease.

Is HAVAH Therapeutics a public or private company?

HAVAH Therapeutics is a private company. It is classified as unknown and is currently operating.

When was HAVAH Therapeutics founded?

HAVAH Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is HAVAH Therapeutics based?

HAVAH Therapeutics is headquartered in North Adelaide, Australia, in the Oceania region.

How does HAVAH Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are HAVAH Therapeutics's main competitors?

Direct peers on record are Quantum Leap Healthcare Collaborative, Atossa Therapeutics, Olema Oncology, Context Therapeutics and Sermonix Pharmaceuticals. Others are Jasper Therapeutics and Ashvattha Therapeutics. Dimerix is listed as an emerging player. Broad incumbents are Arvinas and Hologic.

Does HAVAH Therapeutics have an API?

No public API is recorded for HAVAH Therapeutics.

What industry is HAVAH Therapeutics in?

HAVAH Therapeutics's product category is Breast Cancer Therapeutics. Its primary akta.pro industry code is HLAKAFAJ, Breast Oncology. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireHavah Therapeutics Announces SABCS 2026 Poster Acceptance as RECAST Tests Alternatives to Surgery for DCISHavah Therapeutics announced acceptance of a RECAST DCIS trials-in-progress poster for SABCS 2026, testing its investigational HAV-088 implant for hormone receptor-positive ductal carcinoma in situ. The trial evaluates whether endocrine therapy and MRI monitoring can safely select patients for active surveillance, with pooled RECAST data showing 88% of participants remained on surveillance. Longer follow-up is needed to establish efficacy and safety.EIN PresswireHavah Therapeutics Announces SABCS 2026 Poster Acceptance as RECAST Tests Alternatives to Surgery for DCISHavah Therapeutics announced its RECAST DCIS trial poster acceptance at SABCS 2026. Pooled RECAST data showed 22 of 25 participants remained on active surveillance with only grade 1-2 adverse events. The trial tests HAV-088, an investigational implant, as an alternative to surgery for DCIS.Business Wire BlogHavah Therapeutics to Present at the RiseUp For Breast Cancer and Women’s Health ConferenceHavah Therapeutics announced that Professor Stephen Birrell will present at the RiseUp for Breast Cancer and Women's Health Conference in San Francisco on February 20, 2026, showcasing their lead candidate HAV-088, a first-in-class androgen receptor agonist combining testosterone and anastrozole in a subcutaneous implant for hormone receptor positive breast cancer treatment. The presentation will detail their translational framework for "endocrine steering" and their ongoing RECAST DCIS Phase 2 trial evaluating non-surgical treatment of ductal carcinoma in situ. The company is currently enrolling patients in this trial as it advances its novel hormonal implant therapy approach through clinical development.MorningstarHavah Therapeutics to Present at the RiseUp For Breast Cancer and Women’s Health ConferenceHavah Therapeutics announced that Professor Stephen Birrell will present at the RiseUp for Breast Cancer and Women's Health Conference in San Francisco on February 20, 2026, showcasing their lead candidate HAV-088, a first-in-class androgen receptor agonist combining testosterone and low-dose anastrozole in a subcutaneous implant. The presentation will detail their translational framework for "endocrine steering" of hormonally active breast tissue and their prospectively registered pilot trial comparing HAV-088 with tamoxifen in high-risk premenopausal women. The company is currently enrolling patients in RECAST DCIS, a Phase 2 study evaluating non-surgical treatment of ductal carcinoma in situ to prevent progression to breast cancer.SecSEC FORM DHavah Therapeutics, Inc. filed a Form D with the SEC for an exempt securities offering under Rule 506(b). The company raised a total of $507,434 from 14 investors in connection with a business combination transaction.PR NewswireQuantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini GroupQuantum Leap Healthcare Collaborative launched the RECAST DCIS Phase 2 platform trial to evaluate three investigational endocrine therapies as alternatives to surgery for DCIS, enrolling over 300 patients across more than 40 U.S. sites. The trial will assess (Z)-endoxifen from Atossa Therapeutics, HAVAH T+Ai from Havah Therapeutics, and ORSERDU (elacestrant) from Stemline Therapeutics, with the goal of reducing unnecessary surgeries through up to six months of endocrine therapy followed by active surveillance. The study also incorporates biomarker assessment to identify which DCIS patients are at low risk of progression and may safely avoid invasive procedures.GlobeNewswireClarus Therapeutics Reports Third Quarter 2021 Financial and Operating ResultsClarus Therapeutics reported Q3 2021 revenue of $4.3 million, up 93% year-over-year, with JATENZO prescription growth of 132% annually. The company also closed its business combination with Blue Water, debuting on Nasdaq, and announced new license agreements with McGill University and HavaH Therapeutics.PR NewswireClarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast CancerClarus Therapeutics and HavaH Therapeutics announced a licensing agreement in which Clarus acquired exclusive worldwide development and commercialization rights for the drug candidate CLAR-121, excluding Australia. Under the terms of the deal, Clarus will pay HavaH an upfront fee of $500,000 and is eligible for up to $40.75 million in potential milestone payments, while retaining HavaH's rights to promote the product in its home market. The partnership aims to advance CLAR-121 for inflammatory periductal mastitis and potentially estrogen receptor-positive breast cancer, leveraging HavaH's existing clinical data to expedite U.S. Phase 2/3 studies.